- Home
- MNPR vs CRDL Comparison
MNPR vs CRDL Comparison
Compare MNPR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- CRDL
- Stock Information
- Founded
- MNPR 2014
- CRDL 2017
- Country
- MNPR United States
- CRDL Canada
- Employees
- MNPR N/A
- CRDL N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNPR Health Care
- CRDL Health Care
- Exchange
- MNPR Nasdaq
- CRDL Nasdaq
- Market Cap
- MNPR 113.5M
- CRDL 125.7M
- IPO Year
- MNPR 2019
- CRDL N/A
- Fundamental
- Price
- MNPR $30.68
- CRDL $1.37
- Analyst Decision
- MNPR Strong Buy
- CRDL Strong Buy
- Analyst Count
- MNPR 3
- CRDL 3
- Target Price
- MNPR $27.33
- CRDL $9.00
- AVG Volume (30 Days)
- MNPR 93.6K
- CRDL 416.4K
- Earning Date
- MNPR 11-08-2024
- CRDL 11-14-2024
- Dividend Yield
- MNPR N/A
- CRDL N/A
- EPS Growth
- MNPR N/A
- CRDL N/A
- EPS
- MNPR N/A
- CRDL N/A
- Revenue
- MNPR N/A
- CRDL N/A
- Revenue This Year
- MNPR N/A
- CRDL N/A
- Revenue Next Year
- MNPR N/A
- CRDL N/A
- P/E Ratio
- MNPR N/A
- CRDL N/A
- Revenue Growth
- MNPR N/A
- CRDL N/A
- 52 Week Low
- MNPR $1.55
- CRDL $0.79
- 52 Week High
- MNPR $38.50
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- MNPR 76.63
- CRDL 31.77
- Support Level
- MNPR $20.16
- CRDL $1.38
- Resistance Level
- MNPR $25.97
- CRDL $1.67
- Average True Range (ATR)
- MNPR 2.75
- CRDL 0.09
- MACD
- MNPR 0.41
- CRDL -0.01
- Stochastic Oscillator
- MNPR 90.25
- CRDL 25.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.